Acute myeloid leukemia and myelodysplatic syndrome: parenteral-, enteral- and only oral nutrition during remission induction treatment

Acute myeloid leukemia and myelodysplastic syndrome: parenteral-, enteral- and only oral nutrition during remission induction treatment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20839

Enrollment

180

Registered

2020-04-02

Start date

2018-03-27

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia and late stage myelodysplastic syndrome

Interventions

None

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients (= 18 years), newly diagnosed with AML or MDS who will start with intensive remission induction chemotherapy

Exclusion criteria

Exclusion criteria: • Patients with cognitive disorders or severe emotional instability • Patients who are unable to speak, understand or read the Dutch language.

Design outcomes

Primary

Measure	Time frame
Body composition (fat mass (index), fat-free mass (index), muscle mass and body fat distribution).	—

Secondary

Measure	Time frame
Health related quality of life, functional capacity, muscle strength, tolerance of PN, EN and only oral nutrition (i.e. (severity of) nutrition impact symptoms, laboratory serum liver value tests, central venous catheter infections), nutritional status and course of treatment (chemotherapy-induced toxicity, complications, serum liver test abnormalities, duration of hospital stay, treatment-related mortality, progression-free survival, overall survival ). Furthermore, patient-, disease- and treatment- characteristics, and data about nutritional intake will be collected.	—

Measure

Time frame

Health related quality of life, functional capacity, muscle strength, tolerance of PN, EN and only oral nutrition (i.e. (severity of) nutrition impact symptoms, laboratory serum liver value tests, central venous catheter infections), nutritional status and course of treatment (chemotherapy-induced toxicity, complications, serum liver test abnormalities, duration of hospital stay, treatment-related mortality, progression-free survival, overall survival ). Furthermore, patient-, disease- and treatment- characteristics, and data about nutritional intake will be collected.

—

Contacts

Public ContactRianne van Lieshout

Maxima MC

r.vanlieshout@mmc.nl+31408889040

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)